These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 20477424)

  • 1. Peripheral biomarkers of Parkinson's disease as early reporters of central neurodegeneration.
    Fasano M; Alberio T; Lopiano L
    Biomark Med; 2008 Oct; 2(5):465-78. PubMed ID: 20477424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression.
    Marek K; Jennings D; Tamagnan G; Seibyl J
    Ann Neurol; 2008 Dec; 64 Suppl 2():S111-21. PubMed ID: 19127587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical measures of progression in Parkinson's disease.
    Poewe W
    Mov Disord; 2009; 24 Suppl 2():S671-6. PubMed ID: 19877235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases.
    Quinones MP; Kaddurah-Daouk R
    Neurobiol Dis; 2009 Aug; 35(2):165-76. PubMed ID: 19303440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The search for biomarkers in Parkinson's disease: a critical review.
    Antoniades CA; Barker RA
    Expert Rev Neurother; 2008 Dec; 8(12):1841-52. PubMed ID: 19086880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of genomics and proteomics in understanding the role of modifying factors in Parkinson's disease.
    Singh MP; Patel S; Dikshit M; Gupta YK
    Indian J Biochem Biophys; 2006 Apr; 43(2):69-81. PubMed ID: 16955754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological approaches to disease-modifying therapies in Parkinson's disease.
    O'Neill MJ; Siemers ER
    Expert Rev Neurother; 2002 Nov; 2(6):819-34. PubMed ID: 19810916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA biomarkers of Parkinson's disease: developing tools for novel therapies.
    Hennecke G; Scherzer CR
    Biomark Med; 2008 Feb; 2(1):41-53. PubMed ID: 20477362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease: epidemiology, (differential) diagnosis, therapy, relation to dementia.
    Oertel WH
    Arzneimittelforschung; 1995 Mar; 45(3A):386-9. PubMed ID: 7763330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers for Parkinson's disease.
    Graeber MB
    Exp Neurol; 2009 Apr; 216(2):249-53. PubMed ID: 19166835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers in Huntington's and Parkinson's Disease.
    O'Keeffe GC; Michell AW; Barker RA
    Ann N Y Acad Sci; 2009 Oct; 1180():97-110. PubMed ID: 19906264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early diagnosis of Parkinson's disease: recommendations from diagnostic clinical guidelines.
    Pahwa R; Lyons KE
    Am J Manag Care; 2010 Mar; 16 Suppl Implications():S94-9. PubMed ID: 20297872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects.
    Tsai SJ
    Med Hypotheses; 2007; 69(6):1219-21. PubMed ID: 17548170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomics in Parkinson's disease: current trends, translational snags and future possibilities.
    Srivastava G; Singh K; Tiwari MN; Singh MP
    Expert Rev Proteomics; 2010 Feb; 7(1):127-39. PubMed ID: 20121482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ageing, neurodegeneration and Parkinson's disease.
    Hindle JV
    Age Ageing; 2010 Mar; 39(2):156-61. PubMed ID: 20051606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
    Emborg ME
    J Neurosci Methods; 2004 Oct; 139(2):121-43. PubMed ID: 15488225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression analysis of suppression of tumorigenicity 13 gene in patients with Parkinson's disease.
    Shadrina MI; Filatova EV; Karabanov AV; Slominsky PA; Illarioshkin SN; Ivanova-Smolenskaya IA; Limborska SA
    Neurosci Lett; 2010 Apr; 473(3):257-9. PubMed ID: 20193743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease.
    Fumagalli F; Racagni G; Riva MA
    Pharmacogenomics J; 2006; 6(2):95-104. PubMed ID: 16402079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are dopaminergic pathways involved in theory of mind? A study in Parkinson's disease.
    Péron J; Vicente S; Leray E; Drapier S; Drapier D; Cohen R; Biseul I; Rouaud T; Le Jeune F; Sauleau P; Vérin M
    Neuropsychologia; 2009 Jan; 47(2):406-14. PubMed ID: 18845171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.